nach oben

Erschienen in:

26.10.2021 | Breast Oncology

A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients

verfasst von: Natalie Luehmann, MD, Mona Ascha, MD, Emily Chwa, BA, Paige Hackenberger, MD, Kareem Termanini, MD, Christopher Benning, MBA, Danny Sama, MBA, Dylan Felt, BA, Lauren B. Beach, JD, PhD, Dipti Gupta, MD, Swati A. Kulkarni, MD, Sumanas W. Jordan, MD PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Adherence to screening guidelines among transgender and non-binary (TGNB) populations is not well studied. This study examines breast cancer screening patterns among TGNB patients at an urban academic medical center.

Methods

Demographic information, risk factors, and screening mammography were collected. Mammography rates were calculated in populations of interest according to national guidelines, and mammogram person-years were also calculated. Univariate and multivariate logistic regression was performed.

Results

Overall, 253 patients were analyzed: 193 transgender women and non-binary people designated male at birth (TGNB DMAB) and 60 transgender men and non-binary people designated female at birth (TGNB DFAB). The median (interquartile range) age was 53.2 years (42.3–62.6). Most patients had no family history of breast cancer (n = 163, 64.4%) and were on hormone therapy (n = 191, 75.5%). Most patients where White (n = 164, 64.8%), employed (n = 113, 44.7%), and had public insurance (n = 128, 50.6%). TGNB DFAB breast screening rates were low, ranging from 2.0 to 50.0%, as were TGNB DMAB screening rates, ranging from 7.1 to 47.6%. The screening rates among the TGNB DFAB and TGNB DMAB groups did not significantly differ from one another. Among TGNB DFAB patients, univariate analyses showed no significant predictors for mammography. Among TGNB DMAB patients, not being on hormone therapy resulted in fewer odds of undergoing mammography. There were no significant findings on multivariate analyses.

Conclusion

Mammography rates in the TGNB population are lower than institutional and national rates for cisgender patients, which are 77.3% and 66.7–78.4%, respectively. Stage of transition, organs present, hormone therapy, and risk factors should be considered to guide screening.

Nur mit Berechtigung zugänglich

James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The report of the 2015 US Transgender Survey. National Center for Transgender Equality, Washington, DC. 2016. https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf

Hatzenbuehler ML, Phelan JC, Link BG. Stigma as a fundamental cause of population health inequalities. Am J Public Health. 2013;103(5):813–21. https://doi.org/10.2105/AJPH.2012.301069.CrossRefPubMedPubMedCentral

Warren JC, Smalley KB, Barefoot KN. Differences in Psychosocial Predictors of Obesity among LGBT Subgroups. LGBT Health. 2016;3(4):283–91. https://doi.org/10.1089/lgbt.2015.0076.CrossRefPubMed

Kiran T, Davie S, Singh D, Hranilovic S, Pinto AD, Abramovich A, et al. Cancer screening rates among transgender adults. Can Fam Physician. 2019;65(1):30–7.

Messina MP, D’Angelo A, Giovagnoli R, et al. Cancer screenings among sexual and gender minorities by midwives’ point of view. Minerva Obstet Gynecol. 2021.

Whitlock BL, Duda ES, Elson MJ, et al. Primary care in transgender persons. Endocrinol Metab Clin North Am. 2019;48(2):377–90. https://doi.org/10.1016/j.ecl.2019.02.004.CrossRefPubMed

Tabaac AR, Sutter ME, Wall CSJ, Baker KE. Gender identity disparities in cancer screening behaviors. Am J Prev Med. 2018;54(3):385-393. https://doi.org/10.1016/j.amepre.2017.11.009.CrossRef

Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3.2018 NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(11):1362–89. https://doi.org/10.6004/jnccn.2018.0083.CrossRef

Siu AL. Screening for breast cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2016. https://doi.org/10.7326/M15-2886.CrossRefPubMed

10.

Deutsch MB, Radix A, Wesp L. Breast cancer screening, management, and a review of case study literature in transgender populations. Semin Reprod Med. 2017;35(5):434–41. https://doi.org/10.1055/s-0037-1606103.CrossRefPubMed

11.

Stone JP, Hartley RL, Temple-Oberle C. Breast cancer in transgender patients: a systematic review part 2: female to male. Eur J Surg Oncol. 2018;44(10):1463–8. https://doi.org/10.1016/j.ejso.2018.06.021.CrossRefPubMed

12.

Center of Excellence for Transgender Health. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 2nd edn, University of California, San Francisco, CA, 2020

13.

Lund EM, Burgess CM. Sexual and Gender Minority Health Care Disparities: Barriers to Care and Strategies to Bridge the Gap. Prim Care. 2021;48(2):179–89. https://doi.org/10.1016/j.pop.2021.02.007.CrossRefPubMed

14.

Sukumar S, Mittal R, Kalra S. Transgender medicine in primary care. J Pak Med Assoc. 2020;70(10):1862–3.PubMed

15.

Hartley RL, Stone JP, Temple-Oberle C. Breast cancer in transgender patients: a systematic review. Part 1: male to female. Eur J Surg Oncol. 2018;44(10):1455–62. https://doi.org/10.1016/j.ejso.2018.06.035.CrossRefPubMed

16.

Asscheman H, Giltay EJ, Megens JAJ, De Ronde W, Van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164(4):635–42. https://doi.org/10.1530/EJE-10-1038.CrossRefPubMed

17.

Rossouw J, Anderson G, Prentice R, et al. Writing group for the women’s health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321–33. https://doi.org/10.1001/jama.288.3.321.CrossRefPubMed

18.

Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA. 2020;324(4):369–80. https://doi.org/10.1001/jama.2020.9482.CrossRefPubMedPubMedCentral

19.

Bazzi AR, Whorms DS, King DS, Potter J. Adherence to mammography screening guidelines among transgender persons and sexual minority women. Am J Public Health. 2015;105(11):2356–8. https://doi.org/10.2105/AJPH.2015.302851.CrossRefPubMedPubMedCentral

20.

Tenny S, Boktor SW. Incidence. [Updated 19 Apr 2021]. StatPearls. Treasure Island, FL: StatPearls Publishing; 2021 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430746/.

21.

Deutsch MB. UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco, Guidelines for the Primary and Gender-Affiring Care of Transgender and Gender Nonbinary People. 2nd edition. 2016. Available at: https://transcare.ucsf.edu/guidelines. Accessed 26 May 2021.

22.

Mammography. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/fastats/mammography.htm. Accessed July 1, 2021.

23.

Sauer AG, Liu B, Siegel RL, Jemal A, Fedewa SA. Comparing cancer screening estimates: behavioral risk factor surveillance system and national health interview survey. Prev Med (Baltim). 2018;106:94–100. https://doi.org/10.1016/j.ypmed.2017.10.019.CrossRef

24.

Accountable Care Organization. Northwestern Medicine. Available at: https://www.nm.org/for-medical-professionals/for-physicians/northwestern-medicine-physiciannetwork/accountable-care-organization. Accessed July 1, 2021.

25.

de Blok CJ, Dijkman BA, Wiepjes CM, et al. Frequency and outcomes of benign breast biopsies in trans women: a nationwide cohort study. Breast. 2021;57:118–22. https://doi.org/10.1016/j.breast.2021.03.007.CrossRefPubMedPubMedCentral

26.

Gooren LJ, van Trotsenburg MAA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med. 2013;10(12):3129–34. https://doi.org/10.1111/jsm.12319.CrossRefPubMed

27.

Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M. Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev. 2017;39(1):93–107. https://doi.org/10.1093/epirev/mxw003.CrossRefPubMedPubMedCentral

28.

Sterling J, Garcia MM. Cancer screening in the transgender population: A review of current guidelines, best practices, and a proposed care model. Transl Androl Urol. 2020;9(6):2771–85. https://doi.org/10.21037/tau-20-954.CrossRefPubMedPubMedCentral

29.

Kopetti C, Schaffer C, Zaman K, Liapi A, di Summa PG, Bauquis O. Invasive breast cancer in a trans man after bilateral mastectomy: case report and literature review. Clin Breast Cancer. 2021;21(3):e154–7. https://doi.org/10.1016/j.clbc.2020.10.005.CrossRefPubMed

30.

Chotai N, Tang S, Lim H, Lu S. Breast cancer in a female to male transgender patient 20 years post-mastectomy: issues to consider. Breast J. 2019;25(6):1066–70. https://doi.org/10.1111/tbj.13417.CrossRefPubMed

31.

Salibian AA, Axelrod DM, Smith JA, Fischer BA, Agarwal C, Bluebond-Langner R. Oncologic considerations for safe gender-affirming mastectomy: preoperative imaging, pathologic evaluation, counseling, and long-term screening. Plast Reconstr Surg. 2021;147(2):213e–21e. https://doi.org/10.1097/PRS.0000000000007589.CrossRefPubMed

32.

Monstrey S, Selvaggi G, Ceulemans P, et al. Chest-wall contouring surgery in female-to-male transsexuals: a new algorithm. Plast Reconstr Surg. 2008;121(3):849–59. https://doi.org/10.1097/01.prs.0000299921.15447.b2.CrossRefPubMed

33.

Parikh U, Mausner E, Chhor CM, Gao Y, Karrington I, Heller SL. Breast imaging in transgender patients: What the radiologist should know. Radiographics. 2020;40(1):13–27. https://doi.org/10.1148/rg.2020190044.CrossRefPubMed

34.

Fledderus AC, Gout HA, Ogilvie AC, van Loenen DKG. Breast malignancy in female-to-male transsexuals: systematic review, case report, and recommendations for screening. Breast. 2020;53:92–100. https://doi.org/10.1016/j.breast.2020.06.008.CrossRefPubMedPubMedCentral

35.

Williamson C. Providing care to transgender persons: a clinical approach to primary care, hormones, and hiv management. J Assoc Nurses AIDS Care. 2010;21(3):221–9. https://doi.org/10.1016/j.jana.2010.02.004.CrossRefPubMed

36.

Snelgrove JW, Jasudavisius AM, Roiwe BW, Head EM, Bauer GR. “Completely out-at-sea” with “two-gender medicine”: a qualitative analysis of physician-side barriers to providing healthcare for transgender patients. BMC Health Serv Res. 2012;12:110.CrossRef

37.

Clarke CN, Cortina CS, Fayanju OM, Dossett LA, Johnston FM, Wong SL. Breast cancer risk and screening in transgender persons: a call for inclusive Care. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10217-5.CrossRefPubMedPubMedCentral

38.

Pratt-Chapman ML, Ward AR. Provider recommendations are associated with cancer screening of transgender and gender-nonconforming people: a cross-sectional urban survey. Transgender Health. 2020;5(2):80–5. https://doi.org/10.1089/trgh.2019.0083.CrossRefPubMedPubMedCentral

39.

Sheth HS, Grimes VD, Rudge D, et al. Improving pneumococcal vaccination rates in rheumatology patients by using best practice alerts in the electronic health records. J Rheumatol. 2020;48(9):1472–9. https://doi.org/10.3899/jrheum.200806.CrossRefPubMed

40.

Burrell CN, Sharon MJ, Davis S, et al. Using the electronic medical record to increase testing for HIV and hepatitis C virus in an appalachian emergency department. BMC Health Serv Res. 2021;21(1):524. https://doi.org/10.1186/s12913-021-06482-5.CrossRefPubMedPubMedCentral

41.

Ehrenfeld JM, Gottlieb KG, Beach LB, Monahan SE, Fabbri D. Development of a natural language processing algorithm to identify and evaluate transgender patients in electronic health record systems. Ethn Dis. 2019;29:441–50. https://doi.org/10.18865/ed.29.S2.441.CrossRefPubMedPubMedCentral

Titel: A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients
verfasst von: Natalie Luehmann, MD
Mona Ascha, MD
Emily Chwa, BA
Paige Hackenberger, MD
Kareem Termanini, MD
Christopher Benning, MBA
Danny Sama, MBA
Dylan Felt, BA
Lauren B. Beach, JD, PhD
Dipti Gupta, MD
Swati A. Kulkarni, MD
Sumanas W. Jordan, MD PhD
Publikationsdatum: 26.10.2021
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 3/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-021-10932-z

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients